AI & TECHNOLOGY / EVIDENCE INTO PRACTICE

Biological Computing: A Real Experiment Is Not Yet an Investment Case

Separate neuron-computing research, a commercial product and an investable security. Use a worked exposure example before chasing a breakthrough headline.

By Mika vs Guru · 6 October 2026 · 4 minute read

General education, not individual investment advice. Capital is at risk; examples are hypothetical. Read the disclaimer.

A dish of neurons responds to a game. A company builds a device around living cells. A viewer asks for the ticker. Those are three different stages of an investigation, and the evidence for the first cannot answer the last.

In 2022, Kagan and colleagues described DishBrain, a system linking cultured neurons to a simulated game environment with feedback. The paper reports adaptive task behaviour. It does not establish a human-like mind, a replacement for general computing or a future investment return. [Kagan et al. (2022), Neuron: In vitro neurons in a simulated game-world]

Cortical Labs now describes its CL1 as a platform integrating living neurons with computing and life-support hardware. That is a company product description, useful for understanding what it offers, but not independent proof of every performance or commercial claim. [Cortical Labs: CL1 product description]

Keep three folders instead of one exciting story

In the science folder, record the task, controls, measurements and replication questions. What exactly improved, and compared with what? A system performing one constrained task is not evidence that it performs every economically useful task.

In the business folder, look for customers, revenue, costs, operating requirements and the problem the product solves. A laboratory platform can be useful without becoming a mass-market replacement for a laptop. The relevant commercial market may be much narrower than a headline suggests.

In the security folder, identify the legal issuer, the instrument, the exchange or transaction venue, ownership rights, financial disclosures and liquidity. If those details are missing, writing a ticker-shaped word in your notes does not create an investable security.

“Connected to the technology” is not a measure of exposure

Invented example: Listed Company A earns $1 billion of annual revenue. A small division supplying research equipment earns $10 million, and a fictional neuron-computing customer accounts for $1 million of that division’s sales. That customer represents 0.1% of the company’s total revenue.

If those customer sales doubled to $2 million while everything else stayed constant, company revenue would rise from $1 billion to $1.001 billion, an increase of 0.1%. This is simplified revenue arithmetic, not a valuation model or a forecast. It ignores margins, capacity, investment costs and other business changes.

The example shows why a supplier relationship alone tells you little about financial materiality. A “picks and shovels” narrative needs a scale calculation. A fund with a small holding in that supplier introduces another layer between the story and your actual exposure.

A demonstration needs a denominator too

When a product claims efficiency, ask efficiency per what: successful task, training run, device, laboratory or operating hour? Does the measurement include the equipment that maintains the cells and the computers controlling the experiment?

Our proposed comparison sheet records the same task, quality threshold, total equipment boundary, human labour, elapsed time and failure rate for each system. Do not compare a biological component’s power use with an entire data centre’s consumption and treat the difference as a product advantage.

These are questions for future evidence, not claims that a particular provider has misrepresented its measurements. The goal is to make a comparison reproducible enough that another reader could understand its scope.

Be cautious when the investment arrives before the documents

The SEC’s pre-IPO guidance flags unregistered sellers, aggressive pitches and solicitations built around emerging technologies. A genuine company or genuine scientific development does not authenticate every offer using its name. [SEC Investor.gov: Pre-IPO Investment Scams]

This article does not assert a current public listing or offer a route to buy a named company’s shares. If someone approaches you with access, verify the actual issuer and offering documents through independent official channels. Distinguish shares in the company from an interest in a vehicle that may hold shares, a derivative or an unrelated asset using a similar name.

Turn excitement into a research decision

You can finish this exercise interested in the science and undecided about investing. That is a coherent result. “Worth following” and “worth buying at this price” answer different questions.

Keep the blank boxes visible and set a concrete evidence milestone: a replication, a documented customer use or an official financial disclosure. Then revisit when the evidence changes. The breakthrough can remain interesting while your money waits for a separate, defensible case.

Prepared with AI assistance for the Mika vs Guru publishing team. This is not a claim of professional accreditation or independent peer review. How we research, label examples and handle corrections.